Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Purpose
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.
Conditions
- Advanced Malignant Solid Neoplasm
- Anatomic Stage III Breast Cancer AJCC v8
- Anatomic Stage IV Breast Cancer AJCC v8
- Locally Advanced Malignant Solid Neoplasm
- Malignant Female Reproductive System Neoplasm
- Metastatic HER2-Negative Breast Carcinoma
- Metastatic Malignant Solid Neoplasm
- Recurrent Endometrial Carcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Malignant Female Reproductive System Neoplasm
- Recurrent Malignant Solid Neoplasm
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Unresectable HER2-Negative Breast Carcinoma
- Unresectable Malignant Solid Neoplasm
Eligibility
- Eligible Ages
- All ages
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Criteria
Inclusion Criteria:
- Patient must have measurable disease
- Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status
between 0-2 OR patient must have Lansky performance status of >= 50% or Karnofsky
performance status of >= 50%
- Patient must be deemed potentially eligible for a ComboMATCH Treatment Trial as
assessed by the enrolling provider
- All patients must have sequencing results available from a National Cancer Institute
(NCI) credentialed Designated Laboratory (DL)
- Patients must have locally advanced or advanced histologically documented solid
tumors requiring therapy and meet one of the following criteria:
- Patients must have progressed on at least one line of standard systemic therapy
OR
- Patients whose disease has no standard treatment that has been shown to prolong
overall survival
- Patient must meet one of the following requirements:
- Patients 18 years and older who have tumor amenable to minimal risk
image-guided or direct vision biopsy and must be willing and able to undergo a
tumor biopsy to obtain samples for research if the patient is to enroll in a
ComboMATCH treatment trial OR
- Patients 18 years and older who do not have disease that is biopsiable at
minimal risk to the patient must confirm availability of an archival tumor
tissue specimen for submission for research if the patient enrolls to a
ComboMATCH Treatment Trial. This tumor tissue must meet the following criteria:
- Tissue must have been collected within 12 months prior to registration to
the EAY191 Registration Trial
- Patient must not have had a Response Evaluation Criteria in Solid Tumors
(RECIST) response (complete response [CR] or partial response [PR]) to any
intervening therapy after collection of the tissue
- Formalin-fixed paraffin-embedded tumor tissue block(s) or slides must be
available OR
- Patients under 18 years old must confirm availability of an archival tumor
tissue specimen for submission for research if patient enrolls to a ComboMATCH
Treatment Trial. This tumor tissue must meet the following criteria:
- Formalin-fixed paraffin-embedded tumor tissue block(s) or slides must be
available
- NOTE: See specific ComboMATCH Treatment Trial protocol for tissue collection
and management instructions. Performance of the mandatory research biopsy or
submission of pre-trial formalin-fixed paraffin-embedded (FFPE) and collection
and submission of the blood specimens for the integrated studies will be
performed under the consent authority of the specific treatment trial protocol
to which the patient is registered. No procedures to collect specimens for
research only are to be performed for patients registered to the EAY191
Registration Trial only
- NOTE: Each ComboMATCH Treatment Trial contains specific eligibility criteria. If
patient is found to not be eligible for the assigned ComboMATCH Treatment Trial,
indication of ineligibility will trigger re-evaluation and potential assignment to
another Treatment Trial
Study Design
- Phase
- Phase 2
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Single Group Assignment
- Primary Purpose
- Screening
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental EAY191-A2 (Cohort 1, Arm A) |
Cohort 1, Arm A: Patients receive olaparib PO BID and alpelisib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression. |
|
|
Experimental EAY191-A2 (Cohort 2, Arm B) |
Cohort 2, Arm B: Patients receive olaparib PO BID and alpelisib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression. |
|
|
Experimental EAY191-A2 (Cohort 2, Arm C) |
Cohort 2, Arm C: Patients receive olaparib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients experiencing disease progression have the option to migrate to Cohort 3, Arm D. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression. |
|
|
Experimental EAY191-A2 (Cohort 3, Arm D) |
Cohort 3, Arm D: Patients receive olaparib PO BID and alpelisib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression. |
|
|
Experimental EAY191-A3 Combo Cohorts 1, 2, 3, 4 (palbociclib, binimetinib) |
Patients receive palbociclib PO and binimetinib PO throughout the trial. Patients may also undergo biopsy at screening and undergo MRI, CT, bone scan, and collection of blood samples during screening, on study, and/or during follow up. |
|
|
Experimental EAY191-A3 Monotherapy Cohort 1 (binimetinib) |
Patients receive binimetinib PO throughout the trial. Patients may also undergo biopsy at screening and undergo MRI, CT, bone scan, and collection of blood samples during screening, on study, and/or during follow up. |
|
|
Experimental EAY191-A6 Arm I (RAS/RAF/MEK/ERK mutations) |
Patients receive leucovorin IV, oxaliplatin IV, and fluorouracil IV on study. Patients undergo ECHO and MUGA during screening and on study, a CT with contrast, MRI, or a FDG-PET during screening, collection of blood during screening and on study, and a biopsy during screening. Patients may also undergo brain MRI or CT during screening and on study, bone scans on study, and biopsy on study if clinically indicated. |
|
|
Experimental EAY191-A6 Arm II (RAS/RAF/MEK/ERK mutations) |
Patients receive binimetinib PO, leucovorin IV, oxaliplatin IV, and fluorouracil IV on study. Patients undergo ECHO and MUGA during screening and on study, a CT with contrast, MRI, or an FDG-PET during screening, collection of blood during screening and on study, and a biopsy during screening. Patients may also undergo brain MRI or CT during screening and on study, bone scans on study, and biopsy on study if clinically indicated |
|
|
Experimental EAY191-E4 (taxane therapy) |
Patients receive nilotinib hydrochloride monohydrate PO BID on days 1-28 and paclitaxel IV over 1 hour on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI during screening or cycle 1 day 1, every 2 cycles for 1 year, every 3 cycles for patients on study for more than 1 year, and every 4 cycles for patients on study for more than 3 years and may also undergo CT or MRI during follow-up every 3 months for 2 years and then every 6 months for 1 year if clinically indicated. Patients also undergo collection of blood samples at baseline, cycle 2 day 1, and optionally at progression as well as tumor biopsy at baseline and optionally at progression. |
|
|
Experimental EAY191-E5 Cohort I Arm A (sotorasib, panitumumab) |
Patients receive sotorasib PO QD on days 1-28 and panitumumab IV on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study. |
|
|
Active Comparator EAY191-E5 Cohort I Arm B (sotorasib) |
Patients receive sotorasib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross-over to cohort II. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study. |
|
|
Experimental EAY191-E5 Cohort II (sotorasib) |
Patients receive combination therapy as in EAY191-E5 Arm A. |
|
|
Experimental EAY191-N2 Cohort I (Arm I) (NF1 mutations) |
Patients receive fulvestrant IM on day 1 and day 15 of cycle 1 and day 1 of subsequent cycles and binimetinib PO BID on days 15 to 28 of cycle 1 and day 1 through 28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo a CT, MRI, or bone scan, ECHO or MUGA, and tumor biopsy, as well as possible blood sample collection during screening and on study. |
|
|
Experimental EAY191-N2 Cohort I (Arm II) (NF1 mutations) |
Patients receive fulvestrant IM on day 1 and day 15 of cycle 1 and day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who progress on fulvestrant alone may migrate to cohort II if they meet the migration eligibility criteria. Patients not willing to migrate to cohort II will have further therapy at the investigator's discretion. Patients undergo a CT, MRI, or bone scan and tumor biopsy, as well as ECHO or MUGA and possible blood sample collection during screening and on study. |
|
|
Experimental EAY191-N2 Cohort II (NF1 mutations) |
Patients receive fulvestrant IM on day 1 of each cycle and binimetinib PO BID on days 15-28 of cycle 1 and day 1 through 28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo a CT, MRI, or bone scan, ECHO or MUGA and tumor biopsy, as well as possible blood sample collection during screening and on study. |
|
|
Experimental EAY191-N4 Arm I (RAS pathway mutations) |
Patients receive selumetinib PO BID and olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo a tumor biopsy and blood collection during screening and on study, as well as ECHO or MUGA, and CT scans throughout the trial. Patients may undergo bone marrow aspiration or biopsy as clinically indicated. |
|
|
Active Comparator EAY191-N4 Arm II (RAS pathway mutations) |
Patients receive selumetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience progression may elect to cross over to Arm I provided they have not had dose limiting toxicities to monotherapy selumetinib. Patients also undergo a tumor biopsy and blood collection during screening and on study, as well as ECHO or MUGA, and CT scans throughout the trial. Patients may undergo bone marrow aspiration or biopsy as clinically indicated. |
|
|
Active Comparator EAY191-N5 Arm I (neratinib maleate) |
Patients receive neratinib maleate PO QD on days 1-14 of cycle 0 in the absence of disease progression or unacceptable toxicity. Patients then receive neratinib maleate PO QD on days 1-28 of each subsequent cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience progression may crossover to Arm II. Patients undergo ECHO or MUGA during screening and on study, and CT or MRI and collection of blood samples throughout the trial. Patients may also undergo tumor biopsy during screening and on study. |
|
|
Experimental EAY191-N5 Arm II (neratinib maleate,palbociclib) |
Patients receive neratinib maleate PO QD on days 1-14 of cycle 0 in the absence of disease progression or unacceptable toxicity. Patients then receive neratinib maleate PO QD on days 1-28 and palbociclib PO QD on days 1-21 of each subsequent cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening and on study, and CT or MRI and collection of blood samples throughout the trial. Patients may also undergo tumor biopsy during screening and on study. |
|
|
Experimental EAY191-S3 (activating AKT mutation) |
Patients receive paclitaxel IV on days 1, 8, and 15 and ipatasertib PO on days 1-21 of each cycle. Treatment repeats every 28 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo a CT or MRI and blood collection throughout the trial. Patients also undergo a tumor biopsy during screening and optionally during follow-up. |
|
Recruiting Locations
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama 35233
Birmingham, Alabama 35233
University of South Alabama Mitchell Cancer Institute
Mobile, Alabama 36688
Mobile, Alabama 36688
Alaska Women's Cancer Care
Anchorage, Alaska 99508
Anchorage, Alaska 99508
CTCA at Western Regional Medical Center
Goodyear, Arizona 85338
Goodyear, Arizona 85338
Contact:
Site Public Contact
623-207-3000
Site Public Contact
623-207-3000
Kingman Regional Medical Center
Kingman, Arizona 86401
Kingman, Arizona 86401
Mayo Clinic Hospital in Arizona
Phoenix, Arizona 85054
Phoenix, Arizona 85054
Contact:
Site Public Contact
855-776-0015
Site Public Contact
855-776-0015
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Jonesboro, Arkansas 72401
Jonesboro, Arkansas 72401
PCR Oncology
Arroyo Grande, California 93420
Arroyo Grande, California 93420
Mercy Cancer Center - Carmichael
Carmichael, California 95608
Carmichael, California 95608
Mercy San Juan Medical Center
Carmichael, California 95608
Carmichael, California 95608
Mercy Cancer Center - Elk Grove
Elk Grove, California 95758
Elk Grove, California 95758
UC San Diego Health System - Encinitas
Encinitas, California 92024
Encinitas, California 92024
Contact:
Site Public Contact
760-536-7700
Site Public Contact
760-536-7700
UC San Diego Moores Cancer Center
La Jolla, California 92093
La Jolla, California 92093
The Angeles Clinic and Research Institute - West Los Angeles Office
Los Angeles, California 90025
Los Angeles, California 90025
Cedars Sinai Medical Center
Los Angeles, California 90048
Los Angeles, California 90048
Contact:
Site Public Contact
310-423-8965
Site Public Contact
310-423-8965
Children's Hospital of Orange County
Orange, California 92868
Orange, California 92868
Saint Joseph Hospital - Orange
Orange, California 92868
Orange, California 92868
Contact:
Site Public Contact
714-734-6220
Site Public Contact
714-734-6220
Stanford Cancer Institute Palo Alto
Palo Alto, California 94304
Palo Alto, California 94304
Mercy Cancer Center - Rocklin
Rocklin, California 95765
Rocklin, California 95765
Mercy Cancer Center - Sacramento
Sacramento, California 95816
Sacramento, California 95816
UC San Diego Medical Center - Hillcrest
San Diego, California 92103
San Diego, California 92103
Sharp Memorial Hospital
San Diego, California 92123
San Diego, California 92123
UCSF Medical Center-Mission Bay
San Francisco, California 94158
San Francisco, California 94158
Saint John's Cancer Institute
Santa Monica, California 90404
Santa Monica, California 90404
Contact:
Site Public Contact
310-582-7448
Site Public Contact
310-582-7448
Woodland Memorial Hospital
Woodland, California 95695
Woodland, California 95695
UCHealth University of Colorado Hospital
Aurora, Colorado 80045
Aurora, Colorado 80045
Contact:
Site Public Contact
720-848-0650
Site Public Contact
720-848-0650
Poudre Valley Hospital
Fort Collins, Colorado 80524
Fort Collins, Colorado 80524
Contact:
Site Public Contact
970-297-6150
Site Public Contact
970-297-6150
Cancer Care and Hematology-Fort Collins
Fort Collins, Colorado 80528
Fort Collins, Colorado 80528
UCHealth Greeley Hospital
Greeley, Colorado 80631
Greeley, Colorado 80631
Medical Center of the Rockies
Loveland, Colorado 80538
Loveland, Colorado 80538
Contact:
Site Public Contact
970-203-7083
Site Public Contact
970-203-7083
Helen F Graham Cancer Center
Newark, Delaware 19713
Newark, Delaware 19713
Medical Oncology Hematology Consultants PA
Newark, Delaware 19713
Newark, Delaware 19713
UM Sylvester Comprehensive Cancer Center at Aventura
Aventura, Florida 33180
Aventura, Florida 33180
Contact:
Site Public Contact
954-461-2180
Site Public Contact
954-461-2180
UM Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, Florida 33146
Coral Gables, Florida 33146
Contact:
Site Public Contact
305-243-2647
Site Public Contact
305-243-2647
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida 33442
Deerfield Beach, Florida 33442
Contact:
Site Public Contact
305-243-2647
Site Public Contact
305-243-2647
Broward Health Medical Center
Fort Lauderdale, Florida 33316
Fort Lauderdale, Florida 33316
UF Health Cancer Institute - Gainesville
Gainesville, Florida 32610
Gainesville, Florida 32610
Mayo Clinic in Florida
Jacksonville, Florida 32224-9980
Jacksonville, Florida 32224-9980
Contact:
Site Public Contact
855-776-0015
Site Public Contact
855-776-0015
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida 33136
Miami, Florida 33136
Contact:
Site Public Contact
305-243-2647
Site Public Contact
305-243-2647
UM Sylvester Comprehensive Cancer Center at Kendall
Miami, Florida 33176
Miami, Florida 33176
Contact:
Site Public Contact
305-243-2647
Site Public Contact
305-243-2647
University of Miami Sylvester Comprehensive Cancer Center at Sole Mia
North Miami, Florida 33181
North Miami, Florida 33181
UM Sylvester Comprehensive Cancer Center at Plantation
Plantation, Florida 33324
Plantation, Florida 33324
Contact:
Site Public Contact
305-243-2647
Site Public Contact
305-243-2647
Hawaii Cancer Care Inc - Waterfront Plaza
Honolulu, Hawaii 96813
Honolulu, Hawaii 96813
Queen's Cancer Cenrer - POB I
Honolulu, Hawaii 96813
Honolulu, Hawaii 96813
Contact:
Site Public Contact
808-532-0315
Site Public Contact
808-532-0315
Queen's Medical Center
Honolulu, Hawaii 96813
Honolulu, Hawaii 96813
Contact:
Site Public Contact
808-545-8548
Site Public Contact
808-545-8548
Straub Clinic and Hospital
Honolulu, Hawaii 96813
Honolulu, Hawaii 96813
Contact:
Site Public Contact
808-522-4333
Site Public Contact
808-522-4333
University of Hawaii Cancer Center
Honolulu, Hawaii 96813
Honolulu, Hawaii 96813
Contact:
Site Public Contact
808-586-2979
Site Public Contact
808-586-2979
Queen's Cancer Center - Kuakini
Honolulu, Hawaii 96817
Honolulu, Hawaii 96817
Contact:
Site Public Contact
808-531-8521
Site Public Contact
808-531-8521
Kapiolani Medical Center for Women and Children
Honolulu, Hawaii 96826
Honolulu, Hawaii 96826
Contact:
Site Public Contact
808-983-6090
Site Public Contact
808-983-6090
Hawaii Cancer Care - Westridge
‘Aiea, Hawaii 96701
‘Aiea, Hawaii 96701
Pali Momi Medical Center
‘Aiea, Hawaii 96701
‘Aiea, Hawaii 96701
Contact:
Site Public Contact
808-486-6000
Site Public Contact
808-486-6000
The Queen's Medical Center - West Oahu
‘Ewa Beach, Hawaii 96706
‘Ewa Beach, Hawaii 96706
Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho 83706
Boise, Idaho 83706
Saint Luke's Cancer Institute - Boise
Boise, Idaho 83712
Boise, Idaho 83712
Saint Alphonsus Cancer Care Center-Caldwell
Caldwell, Idaho 83605
Caldwell, Idaho 83605
Kootenai Health - Coeur d'Alene
Coeur d'Alene, Idaho 83814
Coeur d'Alene, Idaho 83814
Saint Luke's Cancer Institute - Fruitland
Fruitland, Idaho 83619
Fruitland, Idaho 83619
Saint Luke's Cancer Institute - Meridian
Meridian, Idaho 83642
Meridian, Idaho 83642
Saint Alphonsus Cancer Care Center-Nampa
Nampa, Idaho 83687
Nampa, Idaho 83687
Saint Luke's Cancer Institute - Nampa
Nampa, Idaho 83687
Nampa, Idaho 83687
Kootenai Clinic Cancer Services - Post Falls
Post Falls, Idaho 83854
Post Falls, Idaho 83854
Kootenai Clinic Cancer Services - Sandpoint
Sandpoint, Idaho 83864
Sandpoint, Idaho 83864
Saint Luke's Cancer Institute - Twin Falls
Twin Falls, Idaho 83301
Twin Falls, Idaho 83301
Advocate Good Shepherd Hospital
Barrington, Illinois 60010
Barrington, Illinois 60010
Contact:
Site Public Contact
847-842-4847
Site Public Contact
847-842-4847
Illinois CancerCare-Bloomington
Bloomington, Illinois 61704
Bloomington, Illinois 61704
Illinois CancerCare-Canton
Canton, Illinois 61520
Canton, Illinois 61520
SIH Cancer Institute
Carterville, Illinois 62918
Carterville, Illinois 62918
Illinois CancerCare-Carthage
Carthage, Illinois 62321
Carthage, Illinois 62321
Centralia Oncology Clinic
Centralia, Illinois 62801
Centralia, Illinois 62801
Mount Sinai Hospital Medical Center
Chicago, Illinois 60608
Chicago, Illinois 60608
Northwestern University
Chicago, Illinois 60611
Chicago, Illinois 60611
John H Stroger Jr Hospital of Cook County
Chicago, Illinois 60612
Chicago, Illinois 60612
Contact:
Site Public Contact
312-864-5204
Site Public Contact
312-864-5204
University of Illinois
Chicago, Illinois 60612
Chicago, Illinois 60612
Contact:
Site Public Contact
312-355-3046
Site Public Contact
312-355-3046
University of Chicago Comprehensive Cancer Center
Chicago, Illinois 60637
Chicago, Illinois 60637
Advocate Illinois Masonic Medical Center
Chicago, Illinois 60657
Chicago, Illinois 60657
Contact:
Site Public Contact
773-296-5360
Site Public Contact
773-296-5360
AMG Crystal Lake - Oncology
Crystal Lake, Illinois 60014
Crystal Lake, Illinois 60014
Carle at The Riverfront
Danville, Illinois 61832
Danville, Illinois 61832
Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois 62526
Decatur, Illinois 62526
Decatur Memorial Hospital
Decatur, Illinois 62526
Decatur, Illinois 62526
Northwestern Medicine Cancer Center Kishwaukee
DeKalb, Illinois 60115
DeKalb, Illinois 60115
Illinois CancerCare-Dixon
Dixon, Illinois 61021
Dixon, Illinois 61021
Contact:
Site Public Contact
815-285-7800
Site Public Contact
815-285-7800
Advocate Good Samaritan Hospital
Downers Grove, Illinois 60515
Downers Grove, Illinois 60515
Carle Physician Group-Effingham
Effingham, Illinois 62401
Effingham, Illinois 62401
Crossroads Cancer Center
Effingham, Illinois 62401
Effingham, Illinois 62401
Advocate Sherman Hospital
Elgin, Illinois 60123
Elgin, Illinois 60123
Contact:
Site Public Contact
847-429-2907
Site Public Contact
847-429-2907
Illinois CancerCare-Eureka
Eureka, Illinois 61530
Eureka, Illinois 61530
NorthShore University HealthSystem-Evanston Hospital
Evanston, Illinois 60201
Evanston, Illinois 60201
Contact:
Site Public Contact
847-570-2109
Site Public Contact
847-570-2109
Illinois CancerCare-Galesburg
Galesburg, Illinois 61401
Galesburg, Illinois 61401
Northwestern Medicine Cancer Center Delnor
Geneva, Illinois 60134
Geneva, Illinois 60134
NorthShore University HealthSystem-Glenbrook Hospital
Glenview, Illinois 60026
Glenview, Illinois 60026
Contact:
Site Public Contact
847-570-2109
Site Public Contact
847-570-2109
Northwestern Medicine Glenview Outpatient Center
Glenview, Illinois 60026
Glenview, Illinois 60026
Contact:
Site Public Contact
312-695-1102
Site Public Contact
312-695-1102
Northwestern Medicine Grayslake Outpatient Center
Grayslake, Illinois 60030
Grayslake, Illinois 60030
Contact:
Site Public Contact
312-695-1102
Site Public Contact
312-695-1102
Ingalls Memorial Hospital
Harvey, Illinois 60426
Harvey, Illinois 60426
Advocate South Suburban Hospital
Hazel Crest, Illinois 60429
Hazel Crest, Illinois 60429
Contact:
Site Public Contact
708-799-9995
Site Public Contact
708-799-9995
NorthShore University HealthSystem-Highland Park Hospital
Highland Park, Illinois 60035
Highland Park, Illinois 60035
Contact:
Site Public Contact
847-570-2109
Site Public Contact
847-570-2109
Illinois CancerCare-Kewanee Clinic
Kewanee, Illinois 61443
Kewanee, Illinois 61443
Northwestern Medicine Lake Forest Hospital
Lake Forest, Illinois 60045
Lake Forest, Illinois 60045
AMG Libertyville - Oncology
Libertyville, Illinois 60048
Libertyville, Illinois 60048
Condell Memorial Hospital
Libertyville, Illinois 60048
Libertyville, Illinois 60048
Illinois CancerCare-Macomb
Macomb, Illinois 61455
Macomb, Illinois 61455
Carle Physician Group-Mattoon/Charleston
Mattoon, Illinois 61938
Mattoon, Illinois 61938
Loyola University Medical Center
Maywood, Illinois 60153
Maywood, Illinois 60153
Contact:
Site Public Contact
708-226-4357
Site Public Contact
708-226-4357
UC Comprehensive Cancer Center at Silver Cross
New Lenox, Illinois 60451
New Lenox, Illinois 60451
Carle BroMenn Medical Center
Normal, Illinois 61761
Normal, Illinois 61761
Carle Cancer Institute Normal
Normal, Illinois 61761
Normal, Illinois 61761
Cancer Care Center of O'Fallon
O'Fallon, Illinois 62269
O'Fallon, Illinois 62269
Advocate Christ Medical Center
Oak Lawn, Illinois 60453-2699
Oak Lawn, Illinois 60453-2699
Contact:
Site Public Contact
800-323-8622
Site Public Contact
800-323-8622
Northwestern Medicine Orland Park
Orland Park, Illinois 60462
Orland Park, Illinois 60462
University of Chicago Medicine-Orland Park
Orland Park, Illinois 60462
Orland Park, Illinois 60462
Illinois CancerCare-Ottawa Clinic
Ottawa, Illinois 61350
Ottawa, Illinois 61350
Advocate Lutheran General Hospital
Park Ridge, Illinois 60068
Park Ridge, Illinois 60068
Contact:
Site Public Contact
847-384-3621
Site Public Contact
847-384-3621
Illinois CancerCare-Pekin
Pekin, Illinois 61554
Pekin, Illinois 61554
Illinois CancerCare-Peoria
Peoria, Illinois 61615
Peoria, Illinois 61615
Illinois CancerCare-Peru
Peru, Illinois 61354
Peru, Illinois 61354
Illinois CancerCare-Princeton
Princeton, Illinois 61356
Princeton, Illinois 61356
Mercyhealth Cancer Institute - Rockford
Rockford, Illinois 61114
Rockford, Illinois 61114
Memorial Hospital East
Shiloh, Illinois 62269
Shiloh, Illinois 62269
Southern Illinois University School of Medicine
Springfield, Illinois 62702
Springfield, Illinois 62702
Contact:
Site Public Contact
217-545-7929
Site Public Contact
217-545-7929
Springfield Clinic
Springfield, Illinois 62702
Springfield, Illinois 62702
Contact:
Site Public Contact
800-444-7541
Site Public Contact
800-444-7541
Springfield Memorial Hospital
Springfield, Illinois 62781
Springfield, Illinois 62781
Carle Cancer Center
Urbana, Illinois 61801
Urbana, Illinois 61801
Northwestern Medicine Cancer Center Warrenville
Warrenville, Illinois 60555
Warrenville, Illinois 60555
Illinois CancerCare - Washington
Washington, Illinois 61571
Washington, Illinois 61571
UI Health Care Mission Cancer and Blood - Ankeny Clinic
Ankeny, Iowa 50023
Ankeny, Iowa 50023
Contact:
Site Public Contact
515-241-3305
Site Public Contact
515-241-3305
Mercy Hospital
Cedar Rapids, Iowa 52403
Cedar Rapids, Iowa 52403
Contact:
Site Public Contact
319-365-4673
Site Public Contact
319-365-4673
Oncology Associates at Mercy Medical Center
Cedar Rapids, Iowa 52403
Cedar Rapids, Iowa 52403
Contact:
Site Public Contact
319-363-2690
Site Public Contact
319-363-2690
UI Health Care Mission Cancer and Blood - Des Moines Clinic
Des Moines, Iowa 50309
Des Moines, Iowa 50309
Contact:
Site Public Contact
515-241-3305
Site Public Contact
515-241-3305
Mercy Medical Center - Des Moines
Des Moines, Iowa 50314
Des Moines, Iowa 50314
Contact:
Site Public Contact
515-241-3305
Site Public Contact
515-241-3305
UI Health Care Mission Cancer and Blood - Laurel Clinic
Des Moines, Iowa 50314
Des Moines, Iowa 50314
Contact:
Site Public Contact
515-241-3305
Site Public Contact
515-241-3305
UI Health Care Mission Cancer and Blood - Waukee Clinic
Waukee, Iowa 50263
Waukee, Iowa 50263
Contact:
Site Public Contact
515-241-3305
Site Public Contact
515-241-3305
Saint Joseph Hospital East
Lexington, Kentucky 40509
Lexington, Kentucky 40509
University of Kentucky/Markey Cancer Center
Lexington, Kentucky 40536
Lexington, Kentucky 40536
Contact:
Site Public Contact
859-257-3379
Site Public Contact
859-257-3379
East Jefferson General Hospital
Metairie, Louisiana 70006
Metairie, Louisiana 70006
University Medical Center New Orleans
New Orleans, Louisiana 70112
New Orleans, Louisiana 70112
Ochsner Medical Center Jefferson
New Orleans, Louisiana 70121
New Orleans, Louisiana 70121
Harold Alfond Center for Cancer Care
Augusta, Maine 04330
Augusta, Maine 04330
Contact:
Site Public Contact
207-626-4855
Site Public Contact
207-626-4855
Lafayette Family Cancer Center-EMMC
Brewer, Maine 04412
Brewer, Maine 04412
Contact:
Site Public Contact
800-987-3005
Site Public Contact
800-987-3005
MaineHealth Maine Medical Center- Scarborough
Scarborough, Maine 04074
Scarborough, Maine 04074
MaineHealth Cancer Care and IV Therapy - South Portland
South Portland, Maine 04106
South Portland, Maine 04106
University of Maryland/Greenebaum Cancer Center
Baltimore, Maryland 21201
Baltimore, Maryland 21201
Contact:
Site Public Contact
800-888-8823
Site Public Contact
800-888-8823
Walter Reed National Military Medical Center
Bethesda, Maryland 20889-5600
Bethesda, Maryland 20889-5600
Contact:
Site Public Contact
301-319-2100
Site Public Contact
301-319-2100
National Institutes of Health Clinical Center
Bethesda, Maryland 20892
Bethesda, Maryland 20892
Contact:
Site Public Contact
800-411-1222
Site Public Contact
800-411-1222
UPMC Western Maryland
Cumberland, Maryland 21502
Cumberland, Maryland 21502
Contact:
Site Public Contact
240-964-1400
Site Public Contact
240-964-1400
Tufts Medical Center
Boston, Massachusetts 02111
Boston, Massachusetts 02111
Dana-Farber Cancer Institute
Boston, Massachusetts 02215
Boston, Massachusetts 02215
Contact:
Site Public Contact
877-442-3324
Site Public Contact
877-442-3324
Baystate Medical Center
Springfield, Massachusetts 01199
Springfield, Massachusetts 01199
Tufts Medical Center Cancer Center Stoneham
Stoneham, Massachusetts 02180
Stoneham, Massachusetts 02180
Trinity Health Saint Joseph Mercy Hospital Ann Arbor
Ann Arbor, Michigan 48106
Ann Arbor, Michigan 48106
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan 48109
Ann Arbor, Michigan 48109
Bronson Battle Creek
Battle Creek, Michigan 49017
Battle Creek, Michigan 49017
Trinity Health IHA Medical Group Hematology Oncology - Brighton
Brighton, Michigan 48114
Brighton, Michigan 48114
Trinity Health Medical Center - Brighton
Brighton, Michigan 48114
Brighton, Michigan 48114
University of Michigan - Brighton Center for Specialty Care
Brighton, Michigan 48116
Brighton, Michigan 48116
Contact:
Site Public Contact
800-865-1125
Site Public Contact
800-865-1125
Trinity Health IHA Medical Group Hematology Oncology - Canton
Canton, Michigan 48188
Canton, Michigan 48188
Trinity Health Medical Center - Canton
Canton, Michigan 48188
Canton, Michigan 48188
Chelsea Hospital
Chelsea, Michigan 48118
Chelsea, Michigan 48118
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Chelsea, Michigan 48118
Chelsea, Michigan 48118
OSF Saint Francis Hospital and Medical Group
Escanaba, Michigan 49829
Escanaba, Michigan 49829
Corewell Health Farmington Hills Hospital
Farmington Hills, Michigan 48336
Farmington Hills, Michigan 48336
Contact:
Site Public Contact
248-551-7695
Site Public Contact
248-551-7695
Cancer Hematology Centers - Flint
Flint, Michigan 48503
Flint, Michigan 48503
Genesys Hurley Cancer Institute
Flint, Michigan 48503
Flint, Michigan 48503
Hurley Medical Center
Flint, Michigan 48503
Flint, Michigan 48503
Corewell Health Grand Rapids Hospitals - Butterworth Hospital
Grand Rapids, Michigan 49503
Grand Rapids, Michigan 49503
Trinity Health Grand Rapids Hospital
Grand Rapids, Michigan 49503
Grand Rapids, Michigan 49503
Bronson Methodist Hospital
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
West Michigan Cancer Center
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
Beacon Kalamazoo Cancer Center
Kalamazoo, Michigan 49009
Kalamazoo, Michigan 49009
Contact:
Site Public Contact
574-647-7370
Site Public Contact
574-647-7370
Beacon Kalamazoo
Kalamazoo, Michigan 49048
Kalamazoo, Michigan 49048
Contact:
Site Public Contact
574-647-7370
Site Public Contact
574-647-7370
University of Michigan Health - Sparrow Lansing
Lansing, Michigan 48912
Lansing, Michigan 48912
Trinity Health Saint Mary Mercy Livonia Hospital
Livonia, Michigan 48154
Livonia, Michigan 48154
Henry Ford Saint John Hospital - Macomb Medical
Macomb, Michigan 48044
Macomb, Michigan 48044
Trinity Health Muskegon Hospital
Muskegon, Michigan 49444
Muskegon, Michigan 49444
Corewell Health Lakeland Hospitals - Niles Hospital
Niles, Michigan 49120
Niles, Michigan 49120
Contact:
Site Public Contact
616-391-1230
Site Public Contact
616-391-1230
Cancer and Hematology Centers of Western Michigan - Norton Shores
Norton Shores, Michigan 49444
Norton Shores, Michigan 49444
Michigan Healthcare Professionals Pontiac
Pontiac, Michigan 48341
Pontiac, Michigan 48341
Trinity Health Saint Joseph Mercy Oakland Hospital
Pontiac, Michigan 48341
Pontiac, Michigan 48341
Corewell Health Reed City Hospital
Reed City, Michigan 49677
Reed City, Michigan 49677
Corewell Health William Beaumont University Hospital
Royal Oak, Michigan 48073
Royal Oak, Michigan 48073
Contact:
Site Public Contact
248-551-7695
Site Public Contact
248-551-7695
MyMichigan Medical Center Saginaw
Saginaw, Michigan 48601
Saginaw, Michigan 48601
Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
Saint Joseph, Michigan 49085
Saint Joseph, Michigan 49085
Corewell Health Lakeland Hospitals - Saint Joseph Hospital
Saint Joseph, Michigan 49085
Saint Joseph, Michigan 49085
MyMichigan Medical Center Tawas
Tawas City, Michigan 48764
Tawas City, Michigan 48764
Munson Medical Center
Traverse City, Michigan 49684
Traverse City, Michigan 49684
University of Michigan Health - West
Wyoming, Michigan 49519
Wyoming, Michigan 49519
Huron Gastroenterology PC
Ypsilanti, Michigan 48106
Ypsilanti, Michigan 48106
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
Ypsilanti, Michigan 48197
Ypsilanti, Michigan 48197
Sanford Joe Lueken Cancer Center
Bemidji, Minnesota 56601
Bemidji, Minnesota 56601
Mercy Hospital
Coon Rapids, Minnesota 55433
Coon Rapids, Minnesota 55433
Essentia Health - Deer River Clinic
Deer River, Minnesota 56636
Deer River, Minnesota 56636
Essentia Health Cancer Center
Duluth, Minnesota 55805
Duluth, Minnesota 55805
Fairview Southdale Hospital
Edina, Minnesota 55435
Edina, Minnesota 55435
Essentia Health Hibbing Clinic
Hibbing, Minnesota 55746
Hibbing, Minnesota 55746
Contact:
Site Public Contact
218-786-3308
Site Public Contact
218-786-3308
Fairview Clinics and Surgery Center Maple Grove
Maple Grove, Minnesota 55369
Maple Grove, Minnesota 55369
Saint John's Hospital - Healtheast
Maplewood, Minnesota 55109
Maplewood, Minnesota 55109
Abbott-Northwestern Hospital
Minneapolis, Minnesota 55407
Minneapolis, Minnesota 55407
Mayo Clinic in Rochester
Rochester, Minnesota 55905
Rochester, Minnesota 55905
Contact:
Site Public Contact
855-776-0015
Site Public Contact
855-776-0015
Park Nicollet Clinic - Saint Louis Park
Saint Louis Park, Minnesota 55416
Saint Louis Park, Minnesota 55416
Regions Hospital
Saint Paul, Minnesota 55101
Saint Paul, Minnesota 55101
United Hospital
Saint Paul, Minnesota 55102
Saint Paul, Minnesota 55102
Essentia Health Sandstone
Sandstone, Minnesota 55072
Sandstone, Minnesota 55072
Essentia Health Virginia Clinic
Virginia, Minnesota 55792
Virginia, Minnesota 55792
Baptist Memorial Hospital and Cancer Center-Golden Triangle
Columbus, Mississippi 39705
Columbus, Mississippi 39705
Baptist Cancer Center-Grenada
Grenada, Mississippi 38901
Grenada, Mississippi 38901
Gulfport Memorial Hospital
Gulfport, Mississippi 39502
Gulfport, Mississippi 39502
Baptist Memorial Hospital and Cancer Center-Union County
New Albany, Mississippi 38652
New Albany, Mississippi 38652
Baptist Memorial Hospital and Cancer Center-Oxford
Oxford, Mississippi 38655
Oxford, Mississippi 38655
Baptist Memorial Hospital and Cancer Center-Desoto
Southhaven, Mississippi 38671
Southhaven, Mississippi 38671
Saint Francis Medical Center
Cape Girardeau, Missouri 63703
Cape Girardeau, Missouri 63703
Saint Luke's Hospital
Chesterfield, Missouri 63017
Chesterfield, Missouri 63017
Contact:
Site Public Contact
314-205-6936
Site Public Contact
314-205-6936
Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, Missouri 63376
City of Saint Peters, Missouri 63376
Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri 63141
Creve Coeur, Missouri 63141
Parkland Health Center - Farmington
Farmington, Missouri 63640
Farmington, Missouri 63640
Contact:
Site Public Contact
314-996-5569
Site Public Contact
314-996-5569
Phelps Health Delbert Day Cancer Institute
Rolla, Missouri 65401
Rolla, Missouri 65401
Heartland Regional Medical Center
Saint Joseph, Missouri 64506
Saint Joseph, Missouri 64506
Sainte Genevieve County Memorial Hospital
Sainte Genevieve, Missouri 63670
Sainte Genevieve, Missouri 63670
Contact:
Site Public Contact
314-996-5569
Site Public Contact
314-996-5569
Mercy Hospital Springfield
Springfield, Missouri 65804
Springfield, Missouri 65804
Contact:
Site Public Contact
417-269-4520
Site Public Contact
417-269-4520
Washington University School of Medicine
St Louis, Missouri 63110
St Louis, Missouri 63110
Mercy Hospital South
St Louis, Missouri 63128
St Louis, Missouri 63128
Siteman Cancer Center-South County
St Louis, Missouri 63129
St Louis, Missouri 63129
Missouri Baptist Medical Center
St Louis, Missouri 63131
St Louis, Missouri 63131
Contact:
Site Public Contact
314-996-5569
Site Public Contact
314-996-5569
Siteman Cancer Center at Christian Hospital
St Louis, Missouri 63136
St Louis, Missouri 63136
Mercy Hospital Saint Louis
St Louis, Missouri 63141
St Louis, Missouri 63141
Contact:
Site Public Contact
314-251-7066
Site Public Contact
314-251-7066
Missouri Baptist Sullivan Hospital
Sullivan, Missouri 63080
Sullivan, Missouri 63080
Contact:
Site Public Contact
314-996-5569
Site Public Contact
314-996-5569
BJC Outpatient Center at Sunset Hills
Sunset Hills, Missouri 63127
Sunset Hills, Missouri 63127
Contact:
Site Public Contact
314-996-5569
Site Public Contact
314-996-5569
Community Hospital of Anaconda
Anaconda, Montana 59711
Anaconda, Montana 59711
Billings Clinic Cancer Center
Billings, Montana 59101
Billings, Montana 59101
Bozeman Health Deaconess Hospital
Bozeman, Montana 59715
Bozeman, Montana 59715
Benefis Sletten Cancer Institute
Great Falls, Montana 59405
Great Falls, Montana 59405
Logan Health Medical Center
Kalispell, Montana 59901
Kalispell, Montana 59901
Community Medical Center
Missoula, Montana 59804
Missoula, Montana 59804
OptumCare Cancer Care at Seven Hills
Henderson, Nevada 89052
Henderson, Nevada 89052
OptumCare Cancer Care at Charleston
Las Vegas, Nevada 89102
Las Vegas, Nevada 89102
Alliance for Childhood Diseases/Cure 4 the Kids Foundation
Las Vegas, Nevada 89135
Las Vegas, Nevada 89135
Summerlin Hospital Medical Center
Las Vegas, Nevada 89144
Las Vegas, Nevada 89144
OptumCare Cancer Care at Fort Apache
Las Vegas, Nevada 89148
Las Vegas, Nevada 89148
Renown Regional Medical Center
Reno, Nevada 89502
Reno, Nevada 89502
Hunterdon Medical Center
Flemington, New Jersey 08822
Flemington, New Jersey 08822
Contact:
Site Public Contact
908-237-2330
Site Public Contact
908-237-2330
Monmouth Medical Center Southern Campus
Lakewood, New Jersey 08701
Lakewood, New Jersey 08701
Saint Barnabas Medical Center
Livingston, New Jersey 07039
Livingston, New Jersey 07039
Monmouth Medical Center
Long Branch, New Jersey 07740
Long Branch, New Jersey 07740
Memorial Sloan Kettering Monmouth
Middletown, New Jersey 07748
Middletown, New Jersey 07748
Contact:
Site Public Contact
212-639-7592
Site Public Contact
212-639-7592
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey 08903
New Brunswick, New Jersey 08903
Contact:
Site Public Contact
732-235-7356
Site Public Contact
732-235-7356
Sidney Kimmel Cancer Center Washington Township
Sewell, New Jersey 08080
Sewell, New Jersey 08080
Robert Wood Johnson University Hospital Somerset
Somerville, New Jersey 08876
Somerville, New Jersey 08876
Community Medical Center
Toms River, New Jersey 08755
Toms River, New Jersey 08755
University of New Mexico Cancer Center
Albuquerque, New Mexico 87106
Albuquerque, New Mexico 87106
Roswell Park Cancer Institute
Buffalo, New York 14263
Buffalo, New York 14263
Memorial Sloan Kettering Commack
Commack, New York 11725
Commack, New York 11725
Contact:
Site Public Contact
212-639-7592
Site Public Contact
212-639-7592
Memorial Sloan Kettering Westchester
Harrison, New York 10604
Harrison, New York 10604
Contact:
Site Public Contact
212-639-7592
Site Public Contact
212-639-7592
NYU Langone Hospital - Long Island
Mineola, New York 11501
Mineola, New York 11501
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York 10016
New York, New York 10016
Mount Sinai Hospital
New York, New York 10029
New York, New York 10029
Memorial Sloan Kettering Cancer Center
New York, New York 10065
New York, New York 10065
Contact:
Site Public Contact
212-639-7592
Site Public Contact
212-639-7592
Pluta Cancer Center
Rochester, New York 14623
Rochester, New York 14623
State University of New York Upstate Medical University
Syracuse, New York 13210
Syracuse, New York 13210
Contact:
Site Public Contact
315-464-5476
Site Public Contact
315-464-5476
Montefiore Medical Center-Einstein Campus
The Bronx, New York 10461
The Bronx, New York 10461
Montefiore Medical Center-Weiler Hospital
The Bronx, New York 10461
The Bronx, New York 10461
Montefiore Medical Center - Moses Campus
The Bronx, New York 10467
The Bronx, New York 10467
Cone Health MedCenter Asheboro
Asheboro, North Carolina 27205
Asheboro, North Carolina 27205
Cone Health Cancer Center at Alamance Regional
Burlington, North Carolina 27215
Burlington, North Carolina 27215
Southeastern Medical Oncology Center-Clinton
Clinton, North Carolina 28328
Clinton, North Carolina 28328
Duke University Medical Center
Durham, North Carolina 27710
Durham, North Carolina 27710
Contact:
Site Public Contact
888-275-3853
Site Public Contact
888-275-3853
Southeastern Medical Oncology Center-Goldsboro
Goldsboro, North Carolina 27534
Goldsboro, North Carolina 27534
Cone Health Cancer Center
Greensboro, North Carolina 27403
Greensboro, North Carolina 27403
Cone Health Cancer Center at Drawbridge Parkway
Greensboro, North Carolina 27410
Greensboro, North Carolina 27410
Hayworth Cancer Center
High Point, North Carolina 27262
High Point, North Carolina 27262
Contact:
Site Public Contact
336-802-2500
Site Public Contact
336-802-2500
Southeastern Medical Oncology Center-Jacksonville
Jacksonville, North Carolina 28546
Jacksonville, North Carolina 28546
Duke Women's Cancer Care Raleigh
Raleigh, North Carolina 27607
Raleigh, North Carolina 27607
Contact:
Site Public Contact
919-785-4878
Site Public Contact
919-785-4878
Annie Penn Memorial Hospital
Reidsville, North Carolina 27320
Reidsville, North Carolina 27320
Wake Forest University Health Sciences
Winston-Salem, North Carolina 27157
Winston-Salem, North Carolina 27157
Contact:
Site Public Contact
336-713-6771
Site Public Contact
336-713-6771
Sanford Bismarck Medical Center
Bismarck, North Dakota 58501
Bismarck, North Dakota 58501
Sanford Broadway Medical Center
Fargo, North Dakota 58122
Fargo, North Dakota 58122
Sanford Roger Maris Cancer Center
Fargo, North Dakota 58122
Fargo, North Dakota 58122
UH Seidman Cancer Center at UH Avon Health Center
Avon, Ohio 44011
Avon, Ohio 44011
Contact:
Site Public Contact
800-641-2422
Site Public Contact
800-641-2422
UHHS-Chagrin Highlands Medical Center
Beachwood, Ohio 44122
Beachwood, Ohio 44122
Strecker Cancer Center-Belpre
Belpre, Ohio 45714
Belpre, Ohio 45714
Aultman Health Foundation
Canton, Ohio 44710
Canton, Ohio 44710
Miami Valley Hospital South
Centerville, Ohio 45459
Centerville, Ohio 45459
Adena Regional Medical Center
Chillicothe, Ohio 45601
Chillicothe, Ohio 45601
Good Samaritan Hospital - Cincinnati
Cincinnati, Ohio 45220
Cincinnati, Ohio 45220
Case Western Reserve University
Cleveland, Ohio 44106
Cleveland, Ohio 44106
Cleveland Clinic Cancer Center/Fairview Hospital
Cleveland, Ohio 44111
Cleveland, Ohio 44111
Cleveland Clinic Foundation
Cleveland, Ohio 44195
Cleveland, Ohio 44195
Ohio State University Comprehensive Cancer Center
Columbus, Ohio 43210
Columbus, Ohio 43210
Mount Carmel East Hospital
Columbus, Ohio 43213
Columbus, Ohio 43213
Columbus Oncology and Hematology Associates Inc
Columbus, Ohio 43214
Columbus, Ohio 43214
Riverside Methodist Hospital
Columbus, Ohio 43214
Columbus, Ohio 43214
Grant Medical Center
Columbus, Ohio 43215
Columbus, Ohio 43215
The Mark H Zangmeister Center
Columbus, Ohio 43219
Columbus, Ohio 43219
Doctors Hospital
Columbus, Ohio 43228
Columbus, Ohio 43228
Miami Valley Hospital
Dayton, Ohio 45409
Dayton, Ohio 45409
Premier Blood and Cancer Center
Dayton, Ohio 45409
Dayton, Ohio 45409
Contact:
Site Public Contact
937-276-8320
Site Public Contact
937-276-8320
Miami Valley Hospital North
Dayton, Ohio 45415
Dayton, Ohio 45415
Delaware Health Center-Grady Cancer Center
Delaware, Ohio 43015
Delaware, Ohio 43015
Grady Memorial Hospital
Delaware, Ohio 43015
Delaware, Ohio 43015
Columbus Oncology and Hematology Associates
Dublin, Ohio 43016
Dublin, Ohio 43016
Dublin Methodist Hospital
Dublin, Ohio 43016
Dublin, Ohio 43016
Atrium Medical Center-Middletown Regional Hospital
Franklin, Ohio 45005-1066
Franklin, Ohio 45005-1066
Miami Valley Cancer Care and Infusion
Greenville, Ohio 45331
Greenville, Ohio 45331
Contact:
Site Public Contact
937-569-7515
Site Public Contact
937-569-7515
Kettering Medical Center
Kettering, Ohio 45429
Kettering, Ohio 45429
Fairfield Medical Center
Lancaster, Ohio 43130
Lancaster, Ohio 43130
OhioHealth Mansfield Hospital
Mansfield, Ohio 44903
Mansfield, Ohio 44903
OhioHealth Marion General Hospital
Marion, Ohio 43302
Marion, Ohio 43302
Memorial Hospital
Marysville, Ohio 43040
Marysville, Ohio 43040
Hillcrest Hospital Cancer Center
Mayfield Heights, Ohio 44124
Mayfield Heights, Ohio 44124
UH Seidman Cancer Center at Lake Health Mentor Campus
Mentor, Ohio 44060
Mentor, Ohio 44060
Knox Community Hospital
Mount Vernon, Ohio 43050
Mount Vernon, Ohio 43050
Licking Memorial Hospital
Newark, Ohio 43055
Newark, Ohio 43055
Mercy Health - Perrysburg Hospital
Perrysburg, Ohio 43551
Perrysburg, Ohio 43551
Southern Ohio Medical Center
Portsmouth, Ohio 45662
Portsmouth, Ohio 45662
Springfield Regional Cancer Center
Springfield, Ohio 45504
Springfield, Ohio 45504
Springfield Regional Medical Center
Springfield, Ohio 45504
Springfield, Ohio 45504
Mercy Health - Saint Anne Hospital
Toledo, Ohio 43623
Toledo, Ohio 43623
Upper Valley Medical Center
Troy, Ohio 45373
Troy, Ohio 45373
Saint Ann's Hospital
Westerville, Ohio 43081
Westerville, Ohio 43081
Genesis Healthcare System Cancer Care Center
Zanesville, Ohio 43701
Zanesville, Ohio 43701
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma 73104
Oklahoma City, Oklahoma 73104
Providence Newberg Medical Center
Newberg, Oregon 97132
Newberg, Oregon 97132
Saint Alphonsus Cancer Care Center-Ontario
Ontario, Oregon 97914
Ontario, Oregon 97914
Providence Willamette Falls Medical Center
Oregon City, Oregon 97045
Oregon City, Oregon 97045
Providence Portland Medical Center
Portland, Oregon 97213
Portland, Oregon 97213
Providence Saint Vincent Medical Center
Portland, Oregon 97225
Portland, Oregon 97225
Oregon Health and Science University
Portland, Oregon 97239
Portland, Oregon 97239
Lehigh Valley Hospital-Cedar Crest
Allentown, Pennsylvania 18103
Allentown, Pennsylvania 18103
Lehigh Valley Hospital - Muhlenberg
Bethlehem, Pennsylvania 18017
Bethlehem, Pennsylvania 18017
Bryn Mawr Hospital
Bryn Mawr, Pennsylvania 19010
Bryn Mawr, Pennsylvania 19010
Pocono Medical Center
East Stroudsburg, Pennsylvania 18301
East Stroudsburg, Pennsylvania 18301
UPMC Hillman Cancer Center Erie
Erie, Pennsylvania 16505
Erie, Pennsylvania 16505
UPMC Cancer Centers - Arnold Palmer Pavilion
Greensburg, Pennsylvania 15601
Greensburg, Pennsylvania 15601
Contact:
Site Public Contact
724-838-1900
Site Public Contact
724-838-1900
Lehigh Valley Hospital-Hazleton
Hazleton, Pennsylvania 18201
Hazleton, Pennsylvania 18201
UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
Mechanicsburg, Pennsylvania 17050
Mechanicsburg, Pennsylvania 17050
Riddle Memorial Hospital
Media, Pennsylvania 19063
Media, Pennsylvania 19063
UPMC Hillman Cancer Center - Monroeville
Monroeville, Pennsylvania 15146
Monroeville, Pennsylvania 15146
Paoli Memorial Hospital
Paoli, Pennsylvania 19301
Paoli, Pennsylvania 19301
Pennsylvania Hospital
Philadelphia, Pennsylvania 19107
Philadelphia, Pennsylvania 19107
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania 19107
Philadelphia, Pennsylvania 19107
Fox Chase Cancer Center
Philadelphia, Pennsylvania 19111
Philadelphia, Pennsylvania 19111
Contact:
Site Public Contact
215-728-4790
Site Public Contact
215-728-4790
UPMC-Magee Womens Hospital
Pittsburgh, Pennsylvania 15213
Pittsburgh, Pennsylvania 15213
Contact:
Site Public Contact
412-647-2811
Site Public Contact
412-647-2811
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania 15232
Pittsburgh, Pennsylvania 15232
Contact:
Site Public Contact
412-647-8073
Site Public Contact
412-647-8073
UPMC-Passavant Hospital
Pittsburgh, Pennsylvania 15237
Pittsburgh, Pennsylvania 15237
Contact:
Site Public Contact
412-367-6454
Site Public Contact
412-367-6454
Guthrie Medical Group PC-Robert Packer Hospital
Sayre, Pennsylvania 18840
Sayre, Pennsylvania 18840
Contact:
Site Public Contact
800-836-0388
Site Public Contact
800-836-0388
Asplundh Cancer Pavilion
Willow Grove, Pennsylvania 19090
Willow Grove, Pennsylvania 19090
Lankenau Medical Center
Wynnewood, Pennsylvania 19096
Wynnewood, Pennsylvania 19096
Women and Infants Hospital
Providence, Rhode Island 02905
Providence, Rhode Island 02905
Contact:
Site Public Contact
401-274-1122
Site Public Contact
401-274-1122
Roger Williams Medical Center
Providence, Rhode Island 02908
Providence, Rhode Island 02908
Prisma Health Cancer Institute - Spartanburg
Boiling Springs, South Carolina 29316
Boiling Springs, South Carolina 29316
Prisma Health Richland Hospital
Columbia, South Carolina 29203
Columbia, South Carolina 29203
Prisma Health Cancer Institute - Easley
Easley, South Carolina 29640
Easley, South Carolina 29640
Saint Francis Hospital
Greenville, South Carolina 29601
Greenville, South Carolina 29601
BI-LO Charities Children's Cancer Center
Greenville, South Carolina 29605
Greenville, South Carolina 29605
Prisma Health Cancer Institute - Butternut
Greenville, South Carolina 29605
Greenville, South Carolina 29605
Prisma Health Cancer Institute - Faris
Greenville, South Carolina 29605
Greenville, South Carolina 29605
Saint Francis Cancer Center
Greenville, South Carolina 29607
Greenville, South Carolina 29607
Prisma Health Cancer Institute - Eastside
Greenville, South Carolina 29615
Greenville, South Carolina 29615
Prisma Health Cancer Institute - Greer
Greer, South Carolina 29650
Greer, South Carolina 29650
Prisma Health Cancer Institute - Seneca
Seneca, South Carolina 29672
Seneca, South Carolina 29672
Rapid City Regional Hospital
Rapid City, South Dakota 57701
Rapid City, South Dakota 57701
Sanford Cancer Center Oncology Clinic
Sioux Falls, South Dakota 57104
Sioux Falls, South Dakota 57104
Sanford USD Medical Center - Sioux Falls
Sioux Falls, South Dakota 57117-5134
Sioux Falls, South Dakota 57117-5134
Baptist Memorial Hospital and Cancer Center-Collierville
Collierville, Tennessee 38017
Collierville, Tennessee 38017
Ballad Health Cancer Care - Kingsport
Kingsport, Tennessee 37660
Kingsport, Tennessee 37660
Baptist Memorial Hospital and Cancer Center-Memphis
Memphis, Tennessee 38120
Memphis, Tennessee 38120
Vanderbilt Breast Center at One Hundred Oaks
Nashville, Tennessee 37204
Nashville, Tennessee 37204
Contact:
Site Public Contact
800-811-8480
Site Public Contact
800-811-8480
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee 37232
Nashville, Tennessee 37232
Contact:
Site Public Contact
800-811-8480
Site Public Contact
800-811-8480
Hendrick Medical Center
Abilene, Texas 79601
Abilene, Texas 79601
Contact:
Site Public Contact
325-670-6340
Site Public Contact
325-670-6340
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas 75390
Dallas, Texas 75390
Lyndon Baines Johnson General Hospital
Houston, Texas 77026-1967
Houston, Texas 77026-1967
Contact:
Site Public Contact
713-566-5000
Site Public Contact
713-566-5000
M D Anderson Cancer Center
Houston, Texas 77030
Houston, Texas 77030
Scott and White Memorial Hospital
Temple, Texas 76508
Temple, Texas 76508
Contact:
Site Public Contact
254-724-5407
Site Public Contact
254-724-5407
University of Virginia Cancer Center
Charlottesville, Virginia 22908
Charlottesville, Virginia 22908
Inova Schar Cancer Institute
Fairfax, Virginia 22031
Fairfax, Virginia 22031
Inova Fairfax Hospital
Falls Church, Virginia 22042
Falls Church, Virginia 22042
Henrico Doctor's Hospital
Richmond, Virginia 23229
Richmond, Virginia 23229
Contact:
Site Public Contact
804-591-4152
Site Public Contact
804-591-4152
VCU Massey Cancer Center at Stony Point
Richmond, Virginia 23235
Richmond, Virginia 23235
VCU Massey Comprehensive Cancer Center
Richmond, Virginia 23298
Richmond, Virginia 23298
Carilion Roanoke Memorial Hospital
Roanoke, Virginia 24033
Roanoke, Virginia 24033
Contact:
Site Public Contact
540-985-8510
Site Public Contact
540-985-8510
VCU Community Memorial Health Center
South Hill, Virginia 23970
South Hill, Virginia 23970
Swedish Cancer Institute-Edmonds
Edmonds, Washington 98026
Edmonds, Washington 98026
Swedish Cancer Institute-Issaquah
Issaquah, Washington 98029
Issaquah, Washington 98029
Providence Regional Cancer System-Lacey
Lacey, Washington 98503
Lacey, Washington 98503
Valley Medical Center
Renton, Washington 98055
Renton, Washington 98055
Swedish Medical Center-First Hill
Seattle, Washington 98122
Seattle, Washington 98122
Providence Saint Mary Regional Cancer Center
Walla Walla, Washington 99362
Walla Walla, Washington 99362
Edwards Comprehensive Cancer Center
Huntington, West Virginia 25701
Huntington, West Virginia 25701
West Virginia University Healthcare
Morgantown, West Virginia 26506
Morgantown, West Virginia 26506
ThedaCare Regional Cancer Center
Appleton, Wisconsin 54911
Appleton, Wisconsin 54911
ThedaCare Regional Medical Center - Appleton
Appleton, Wisconsin 54911
Appleton, Wisconsin 54911
Duluth Clinic Ashland
Ashland, Wisconsin 54806
Ashland, Wisconsin 54806
ThedaCare Cancer Care - Berlin
Berlin, Wisconsin 54923
Berlin, Wisconsin 54923
Aurora Cancer Care-Southern Lakes VLCC
Burlington, Wisconsin 53105
Burlington, Wisconsin 53105
Marshfield Medical Center-EC Cancer Center
Eau Claire, Wisconsin 54701
Eau Claire, Wisconsin 54701
Aurora Health Care Germantown Health Center
Germantown, Wisconsin 53022
Germantown, Wisconsin 53022
Aurora Cancer Care-Grafton
Grafton, Wisconsin 53024
Grafton, Wisconsin 53024
Saint Vincent Hospital Cancer Center Green Bay
Green Bay, Wisconsin 54301
Green Bay, Wisconsin 54301
Saint Vincent Hospital Cancer Center at Saint Mary's
Green Bay, Wisconsin 54303
Green Bay, Wisconsin 54303
Aurora BayCare Medical Center
Green Bay, Wisconsin 54311
Green Bay, Wisconsin 54311
Mercyhealth Hospital and Cancer Center - Janesville
Janesville, Wisconsin 53548
Janesville, Wisconsin 53548
Aurora Cancer Care-Kenosha South
Kenosha, Wisconsin 53142
Kenosha, Wisconsin 53142
Gundersen Lutheran Medical Center
La Crosse, Wisconsin 54601
La Crosse, Wisconsin 54601
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
Madison, Wisconsin 53718
Madison, Wisconsin 53718
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin 53792
Madison, Wisconsin 53792
Aurora Bay Area Medical Group-Marinette
Marinette, Wisconsin 54143
Marinette, Wisconsin 54143
Marshfield Medical Center-Marshfield
Marshfield, Wisconsin 54449
Marshfield, Wisconsin 54449
Aurora Cancer Care-Milwaukee
Milwaukee, Wisconsin 53209
Milwaukee, Wisconsin 53209
Aurora Saint Luke's Medical Center
Milwaukee, Wisconsin 53215
Milwaukee, Wisconsin 53215
Aurora Sinai Medical Center
Milwaukee, Wisconsin 53233
Milwaukee, Wisconsin 53233
Marshfield Medical Center - Minocqua
Minocqua, Wisconsin 54548
Minocqua, Wisconsin 54548
ProHealth D N Greenwald Center
Mukwonago, Wisconsin 53149
Mukwonago, Wisconsin 53149
ThedaCare Regional Medical Center - Neenah
Neenah, Wisconsin 54956
Neenah, Wisconsin 54956
ThedaCare Cancer Care - New London
New London, Wisconsin 54961
New London, Wisconsin 54961
Cancer Center of Western Wisconsin
New Richmond, Wisconsin 54017
New Richmond, Wisconsin 54017
ProHealth Oconomowoc Memorial Hospital
Oconomowoc, Wisconsin 53066
Oconomowoc, Wisconsin 53066
Contact:
Site Public Contact
262-928-7878
Site Public Contact
262-928-7878
Saint Vincent Hospital Cancer Center at Oconto Falls
Oconto Falls, Wisconsin 54154
Oconto Falls, Wisconsin 54154
ThedaCare Cancer Care - Oshkosh
Oshkosh, Wisconsin 54904
Oshkosh, Wisconsin 54904
Vince Lombardi Cancer Clinic - Oshkosh
Oshkosh, Wisconsin 54904
Oshkosh, Wisconsin 54904
Aurora Cancer Care-Racine
Racine, Wisconsin 53406
Racine, Wisconsin 53406
Marshfield Medical Center-Rice Lake
Rice Lake, Wisconsin 54868
Rice Lake, Wisconsin 54868
ThedaCare Cancer Care - Shawano
Shawano, Wisconsin 54166
Shawano, Wisconsin 54166
Saint Vincent Hospital Cancer Center at Sheboygan
Sheboygan, Wisconsin 53081
Sheboygan, Wisconsin 53081
Sheboygan Physicians Group
Sheboygan, Wisconsin 53081
Sheboygan, Wisconsin 53081
Vince Lombardi Cancer Clinic-Sheboygan
Sheboygan, Wisconsin 53081
Sheboygan, Wisconsin 53081
Marshfield Medical Center-River Region at Stevens Point
Stevens Point, Wisconsin 54482
Stevens Point, Wisconsin 54482
Saint Vincent Hospital Cancer Center at Sturgeon Bay
Sturgeon Bay, Wisconsin 54235-1495
Sturgeon Bay, Wisconsin 54235-1495
Aurora Medical Center in Summit
Summit, Wisconsin 53066
Summit, Wisconsin 53066
Vince Lombardi Cancer Clinic-Two Rivers
Two Rivers, Wisconsin 54241
Two Rivers, Wisconsin 54241
UW Cancer Center at ProHealth Care
Waukesha, Wisconsin 53188
Waukesha, Wisconsin 53188
ThedaCare Cancer Care - Waupaca
Waupaca, Wisconsin 54981
Waupaca, Wisconsin 54981
Aurora Cancer Care-Milwaukee West
Wauwatosa, Wisconsin 53226
Wauwatosa, Wisconsin 53226
Aurora West Allis Medical Center
West Allis, Wisconsin 53227
West Allis, Wisconsin 53227
Marshfield Medical Center - Weston
Weston, Wisconsin 54476
Weston, Wisconsin 54476
Puerto Rico Hematology Oncology Group
Bayamón, Puerto Rico 00961
Bayamón, Puerto Rico 00961
Contact:
Site Public Contact
787-780-2865
Site Public Contact
787-780-2865
Doctors Cancer Center
Manatí, Puerto Rico 00674
Manatí, Puerto Rico 00674
Contact:
Site Public Contact
787-621-4397
Site Public Contact
787-621-4397
Centro Comprensivo de Cancer de UPR
San Juan, Puerto Rico 00927
San Juan, Puerto Rico 00927
PROncology
San Juan, Puerto Rico 00927
San Juan, Puerto Rico 00927
More Details
- NCT ID
- NCT05564377
- Status
- Recruiting
- Sponsor
- National Cancer Institute (NCI)
Detailed Description
PRIMARY OBJECTIVE: I. To register, allocate, and assign patients to ComboMATCH treatment trials. SECONDARY OBJECTIVES: I. To evaluate the rate of positive outcomes in defined cohorts within treatment trials of treatment combinations including targeted therapies for molecularly defined populations, and also in the subset of treatment trials where the treatments are supported by in vivo models. II. To perform quality control of the patients registered in the form of pathological confirmation of disease and sub-type to confirm diagnosis and treatment arm allocation. SECONDARY CORRELATIVE OBJECTIVES: I. Assess the concordance of the central molecular characterization of the pre-treatment biopsy samples with the genetic readouts from the Designated Laboratories (DLs) for patients enrolled on the ComboMATCH treatment trials. II. To assess how the registration diagnostic tumor mutation profile and pre-treatment biopsy profile compare to the circulating tumor-derived deoxyribonucleic acid (ctDNA) mutation profile from plasma. EXPLORATORY OBJECTIVE: I. Assess association between ComboMATCH treatment trials outcomes (positive or negative) with the type of rationale for the selected drug combinations and the type of rationale for the gene variant/combination for selection (e.g., whether the trial was based on targeted therapies for molecularly defined populations, those that were supported by in vivo models, and those that were supported by empiric clinical data). OUTLINE: REGISTRATION: Patients undergo tumor mutational screening of previously-collected tumor samples for specific, pre-defined mutations, amplifications, or translocations of interest via tumor sequencing. Patients who are 18 years or older and have biopsiable disease undergo a new biopsy for research purposes prior to initiating treatment on the ComboMATCH treatment trial. TREATMENT: Patients with mutations targeted to investigational combination therapies are assigned to 1 of 20 treatment subprotocols. EAY191-N4: Patients with RAS pathway mutant ovarian or endometrial cancer are randomized to 1 of 2 arms. ARM I: Patients receive selumetinib orally (PO) twice daily (BID) and olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo a tumor biopsy and blood collection during screening and on study, as well as echocardiogram (ECHO) or multigated acquisition (MUGA), and computed tomography (CT) scans throughout the trial. Patients may undergo bone marrow aspiration or biopsy as clinically indicated. ARM II: Patients receive selumetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience progression may elect to cross over to Arm I provided they have not had dose limiting toxicities to monotherapy selumetinib. Patients also undergo a tumor biopsy and blood collection during screening and on study, as well as ECHO or MUGA, and CT scans throughout the trial. Patients may undergo bone marrow aspiration or biopsy as clinically indicated. EAY191-N2: Patients with inactivating or inferred inactivating NF1 alterations, and hormone receptor positive, HER2-negative metastatic breast cancer. Patients who are fulvestrant naive are assigned to Cohort I, while patients who are fulvestrant resistant are assigned to Cohort II. COHORT I: Patients are randomized to 1 of 2 arms. ARM I:Patients receive fulvestrant intramuscularly (IM) on day 1 and day 15 of cycle 1 and day 1 of subsequent cycles and binimetinib PO BID on days 15 to 28 of cycle 1 and day 1 through 28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo a CT, magnetic resonance imaging (MRI), or bone scan, ECHO or MUGA, and tumor biopsy, as well as possible blood sample collection during screening and on study. ARM II: Patients receive fulvestrant IM on day 1 and day 15 of cycle 1 and day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who progress on fulvestrant alone may migrate to cohort II if they meet the migration eligibility criteria. Patients not willing to migrate to cohort II will have further therapy at the investigator's discretion. Patients undergo a CT, MRI, or bone scan and tumor biopsy, as well as ECHO or MUGA and possible blood sample collection during screening and on study. COHORT II: Patients receive fulvestrant IM on day 1 of each cycle and binimetinib PO BID on days 15-28 of cycle 1 and day 1 through 28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo a CT, MRI, or bone scan, ECHO or MUGA and tumor biopsy, as well as possible blood sample collection during screening and on study. EAY191-E4: Patients with solid tumors who previously underwent taxane therapy. Patients receive nilotinib hydrochloride monohydrate PO BID on days 1-28 and paclitaxel intravenously (IV) over 1 hour on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI during screening or cycle 1 day 1, every 2 cycles for 1 year, every 3 cycles for patients on study for more than 1 year, and every 4 cycles for patients on study for more than 3 years and may also undergo CT or MRI during follow-up every 3 months for 2 years and then every 6 months for 1 year if clinically indicated. Patients also undergo collection of blood samples at baseline, cycle 2 day 1, and optionally at progression as well as tumor biopsy at baseline and optionally at progression. EAY191-A3: Patients with KRAS/NRAS/BRAF mutated low-grade serous ovarian cancer (LGSOC) naive to MEK or CDK4/6 inhibitor therapy are randomized to either combination cohort 1 or monotherapy cohort 1. Patients with LGSOC who have received prior MEK inhibitor therapy are assigned to combination cohort 2. Patients with KRAS/NRAS/HRAS/non-V600E BRAF mutated pancreatic cancer are assigned to combination cohort 3. Patients with all other KRAS/NRAS/HRAS mutated tumor types (excluding LGSOC, non-small cell lung cancer, colorectal cancer, pancreatic, and melanoma) are assigned to combination cohort 4. COMBINATION COHORTS 1, 2, 3, 4: Patients receive palbociclib PO and binimetinib PO throughout the trial. Patients may also undergo biopsy at screening and undergo MRI, CT, bone scan, and collection of blood samples during screening, on study, and/or during follow up. MONOTHERAPY COHORT 1: Patients receive binimetinib PO throughout the trial. Patients may also undergo biopsy at screening and undergo MRI, CT, bone scan, and collection of blood samples during screening, on study, and/or during follow up. EAY191-S3: Patients with an activating AKT mutation solid tumor. Patients receive paclitaxel IV on days 1, 8, and 15 and ipatasertib PO on days 1-21 of each cycle. Treatment repeats every 28 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo a CT or MRI and blood collection throughout the trial. Patients also undergo a tumor biopsy during screening and optionally during follow-up. EAY191-A6: Patients with RAS/RAF/MEK/ERK mutant biliary tract cancers are randomized to 1 of 2 arms. ARM 1: Patients receive leucovorin IV, oxaliplatin IV, and fluorouracil IV on study. Patients undergo echocardiogram (ECHO) and multigated acquisition scan (MUGA) during screening and on study, a CT with contrast, MRI, or a fludeoxyglucose F-18 positron emission tomography (FDG-PET) during screening, collection of blood during screening and on study, and a biopsy during screening. Patients may also undergo brain MRI or CT during screening and on study, bone scans on study, and biopsy on study if clinically indicated. ARM 2: Patients receive binimetinib PO, leucovorin IV, oxaliplatin IV, and fluorouracil IV on study. Patients undergo ECHO and MUGA during screening and on study, a CT with contrast, MRI, or an FDG-PET during screening, collection of blood during screening and on study, and a biopsy during screening. Patients may also undergo brain MRI or CT during screening and on study, bone scans on study, and biopsy on study if clinically indicated. EAY191-E5: Patients are assigned to 1 of 2 cohorts. COHORT I: Patients who have never received a KRAS G12C inhibitor are randomized to arms A or B. ARM A: Patients receive sotorasib PO once daily (QD) on days 1-28 and panitumumab intravenously IV on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study. ARM B: Patients receive sotorasib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross-over to cohort II. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study. COHORT II: Patients who have received a KRAS G12C inhibitor are assigned to arm C. ARM C: Patients receive combination therapy as in Arm A. EAY191-A2: Patients are assigned to 1 of 3 cohorts. COHORT 1: PARP-inhibitor naive patients are assigned to Arm A. ARM A: Patients receive olaparib PO BID and alpelisib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression. COHORT 2: PARP-inhibitor naive patients are randomized to 1 of 2 arms. ARM B: Patients receive olaparib PO BID and alpelisib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression. ARM C: Patients receive olaparib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients experiencing disease progression have the option to migrate to Cohort 3, Arm D. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression. COHORT 3: PARP-inhibitor resistant patients are assigned to Arm D. ARM D: Patients receive olaparib PO BID and alpelisib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression. EAY191-N5: Patients are randomized to 1 of 2 arms. ARM I: Patients receive neratinib maleate PO QD on days 1-14 of cycle 0 in the absence of disease progression or unacceptable toxicity. Patients then receive neratinib maleate PO QD on days 1-28 of each subsequent cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience progression may crossover to Arm II. Patients undergo ECHO or MUGA during screening and on study, and CT or MRI and collection of blood samples throughout the trial. Patients may also undergo tumor biopsy during screening and on study. ARM II: Patients receive neratinib maleate PO QD on days 1-14 of cycle 0 in the absence of disease progression or unacceptable toxicity. Patients then receive neratinib maleate PO QD on days 1-28 and palbociclib PO QD on days 1-21 of each subsequent cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening and on study, and CT or MRI and collection of blood samples throughout the trial. Patients may also undergo tumor biopsy during screening and on study.